Gilteritinib + Cytarabine + Mitoxantrone + Etoposide + G-CSF + Fludarabine

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

AML With FLT3 Mutation

Conditions

AML With FLT3 Mutation

Trial Timeline

Oct 25, 2017 → Mar 31, 2026

NCT ID

NCT03182244

About Gilteritinib + Cytarabine + Mitoxantrone + Etoposide + G-CSF + Fludarabine

Gilteritinib + Cytarabine + Mitoxantrone + Etoposide + G-CSF + Fludarabine is a phase 3 stage product being developed by Astellas Pharma for AML With FLT3 Mutation. The current trial status is active. This product is registered under clinical trial identifier NCT03182244. Target conditions include AML With FLT3 Mutation.

What happened to similar drugs?

20 of 20 similar drugs in AML With FLT3 Mutation were approved

Approved (20) Terminated (0) Active (0)

✅Tamsulosin OCASAstellas PharmaApproved

✅Mirtazapine TabletsSun PharmaceuticalApproved

✅MecobalaminEisaiApproved

✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved

✅Atomoxetine Hydrochloride + placeboEli LillyApproved

✅Eslicarbazepine acetate + Eslicarbazepine AcetateSumitomo PharmaApproved

✅OROS MethylphenidateJohnson & JohnsonApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03182244	Phase 3	Active	Oct 25, 2017	Mar 31, 2026	AML With FLT3 Mutation

Competing Products

20 competing products in AML With FLT3 Mutation

See all competitors

Product	Company	Stage	Hype Score
DFN-15	Dr. Reddy's Laboratories	Phase 2	32
LY3461767 + Placebo	Eli Lilly	Phase 1	29
Glucagon + Insulin	Abvance Therapeutics	Phase 1	19
CT-P41 + US-licensed Prolia	Celltrion	Phase 3	40
Letrozole	Chugai Pharmaceutical	Phase 2	35
Letrozole	Chugai Pharmaceutical	Phase 2	35
Letrozole	Chugai Pharmaceutical	Phase 2	35
Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapy	Yuhan	Pre-clinical	33
PLX3397 + Temozolomide	Daiichi Sankyo	Phase 1/2	32
DS-5565 + Pregabalin + Placebo tablet + Placebo capsule	Daiichi Sankyo	Phase 3	40
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	35
DS-5565	Daiichi Sankyo	Phase 3	40
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
Pravastatin	Daiichi Sankyo	Pre-clinical	26
DS-5565 + Pregabalin + Placebo tablet + Placebo capsule	Daiichi Sankyo	Phase 3	40
Quizartinib Dihydrochloride	Daiichi Sankyo	Pre-clinical	26
DS-5565 + Pregabalin + Placebo tablet + Placebo capsule	Daiichi Sankyo	Phase 3	40
CS-3150	Daiichi Sankyo	Phase 3	40
roxadustat	Astellas Pharma	Phase 3	40
roxadustat	Astellas Pharma	Phase 3	40